Perl T M, Golub J E
School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Ann Pharmacother. 1998 Jan;32(1):S7-16. doi: 10.1177/106002809803200104.
Nosocomial infections cause significant patient morbidity and mortality. The 2.5 million nosocomial infections that occur each year cost the US healthcare system $5 million to $10 million. Staphylococcus aureus has long been recognized as an important pathogen in human disease and is the most common cause of nosocomial infections.
To describe the epidemiology of S. aureus nosocomial infections that are attributable to patients' endogenous colonization.
Review of the English-language literature and a MEDLINE search (as of September 1997).
The ecologic niche of S. aureus is the anterior nares. The prevalence of S. aureus nasal carriage is approximately 20-25%, but varies among different populations, and is influenced by age, underlying illness, race, certain behaviors, and the environment in which the person lives or works. The link between S. aureus nasal carriage and development of subsequent S. aureus infections has been established in patients on hemodialysis, on continuous ambulatory peritoneal dialysis, and those undergoing surgery. S. aureus nasal carriers have a two-to tenfold increased risk of developing S. aureus surgical site or intravenous catheter infections. Thirty percent of 100% of S. aureus infections are due to endogenous flora and infecting strains were genetically identical to nasal strains. Three treatment strategies may eliminate nasal carriage: locally applied antibiotics or disinfectants, systemic antibiotics, and bacterial interference. Among these strategies, locally applied or systemic antibiotics are most commonly used. Nasal ointments or sprays and oral antibiotics have variable efficacy and their use frequently results in antimicrobial resistance among S. aureus strains. Of the commonly used agents, mupirocin (pseudomonic acid) ointment has been shown to be 97% effective in reducing S. aureus nasal carriage. However, resistance occurs when the ointment has been applied for a prolonged period over large surface areas.
Given the importance of S. aureus nosocomial infections and the increased risk of S. aureus nasal carriage in patients with nosocomial infections, investigators need to study cost-effective strategies to prevent certain types of nosocomial infections or nosocomial infections that occur in specific settings. One potential strategy is to decrease S. aureus nasal carriage among certain patient populations.
医院感染会导致患者出现严重的发病情况和死亡。每年发生的250万例医院感染让美国医疗系统花费500万至1000万美元。金黄色葡萄球菌长期以来一直被认为是人类疾病中的一种重要病原体,也是医院感染最常见的原因。
描述由患者内源性定植引起的金黄色葡萄球菌医院感染的流行病学情况。
对英文文献的综述以及MEDLINE检索(截至1997年9月)。
金黄色葡萄球菌的生态位是前鼻孔。金黄色葡萄球菌鼻腔定植的患病率约为20% - 25%,但在不同人群中有所不同,并受年龄、基础疾病、种族、某些行为以及个人生活或工作环境的影响。金黄色葡萄球菌鼻腔定植与随后发生金黄色葡萄球菌感染之间的联系已在接受血液透析、持续非卧床腹膜透析的患者以及接受手术的患者中得到证实。金黄色葡萄球菌鼻腔携带者发生金黄色葡萄球菌手术部位感染或静脉导管感染的风险增加两到十倍。100%的金黄色葡萄球菌感染中有30%是由内源性菌群引起的,且感染菌株在基因上与鼻腔菌株相同。三种治疗策略可消除鼻腔定植:局部应用抗生素或消毒剂、全身应用抗生素以及细菌干扰。在这些策略中,局部应用或全身应用抗生素最为常用。鼻用软膏或喷雾剂以及口服抗生素的疗效各不相同,且它们的使用常常导致金黄色葡萄球菌菌株产生抗菌耐药性。在常用药物中,莫匹罗星(假单胞菌酸)软膏已被证明在减少金黄色葡萄球菌鼻腔定植方面有97%的有效性。然而,当软膏在大面积上长时间应用时会出现耐药性。
鉴于金黄色葡萄球菌医院感染的重要性以及医院感染患者中金黄色葡萄球菌鼻腔定植风险的增加,研究人员需要研究具有成本效益的策略来预防某些类型的医院感染或在特定环境中发生的医院感染。一种潜在策略是减少某些患者群体中的金黄色葡萄球菌鼻腔定植。